blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3388425

EP3388425 - AMINOAZOLE DERIVATIVE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.06.2021
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  03.07.2020
FormerGrant of patent is intended
Status updated on  26.02.2020
FormerRequest for examination was made
Status updated on  14.09.2018
FormerThe international publication has been made
Status updated on  16.06.2017
Most recent event   Tooltip22.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 24.08.2022  [2022/34]
Applicant(s)For all designated states
Teijin Pharma Limited
2-1, Kasumigaseki 3-chome Chiyoda-ku
Tokyo 100-0013 / JP
[2018/42]
Inventor(s)01 / HOSODA, Shinnosuke
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
02 / UNOKI, Gen
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
03 / WATANABE, Hidekazu
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
04 / SASAKI, Kosuke
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
05 / SHIBATA, Jun
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
06 / YOKOYAMA, Emi
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
07 / HORIE, Kyohei
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
08 / TAKAGI, Kenichiro
c/o Teijin Pharma Limited
2-1 Kasumigaseki 3-chome
Chiyoda-ku
Tokyo 100-0013 / JP
 [2018/42]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2018/42]
Application number, filing date16873130.509.12.2016
[2018/42]
WO2016JP86784
Priority number, dateJP2015024206511.12.2015         Original published format: JP 2015242065
[2018/42]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017099237
Date:15.06.2017
Language:JA
[2017/24]
Type: A1 Application with search report 
No.:EP3388425
Date:17.10.2018
Language:EN
[2018/42]
Type: B1 Patent specification 
No.:EP3388425
Date:05.08.2020
Language:EN
[2020/32]
Search report(s)International search report - published on:JP15.06.2017
(Supplementary) European search report - dispatched on:EP22.07.2019
ClassificationIPC:C07D263/48, C07D277/56, C07C335/12, A61K31/421, A61K31/422, A61K31/4245, A61K31/426, A61K31/427, A61K31/428, A61K31/433, A61K31/4439, A61K31/454, A61K31/4709, A61K31/4725, A61K31/497, A61K31/498, A61K31/501, A61K31/5377, A61P21/00, A61P21/04, A61P43/00
[2019/19]
CPC:
C07D277/56 (EP,US); C07D277/38 (KR); A61K31/421 (EP,KR,US);
A61K31/422 (EP,US); A61K31/4245 (EP,US); A61K31/426 (EP,KR,US);
A61K31/427 (EP,US); A61K31/428 (EP,US); A61K31/433 (EP,US);
A61K31/4439 (EP,KR,US); A61K31/454 (EP,US); A61K31/4709 (EP,KR,US);
A61K31/4725 (EP,US); A61K31/497 (EP,US); A61K31/498 (EP,US);
A61K31/501 (EP,US); A61K31/5377 (EP,US); A61P21/00 (KR);
A61P21/04 (KR); A61P5/26 (EP,US); C07C335/12 (EP,US);
C07C335/18 (EP,US); C07D249/08 (EP,US); C07D263/48 (EP,KR,US);
C07D277/82 (EP,US); C07D413/12 (EP,KR,US); C07D417/12 (EP,KR,US) (-)
Former IPC [2018/42]C07D263/48, A61K31/421, A61K31/422, A61K31/4245, A61K31/426, A61K31/427, A61K31/428, A61K31/433, A61K31/4439, A61K31/454, A61K31/4709, A61K31/4725, A61K31/497, A61K31/498, A61K31/501, A61K31/5377, A61P21/00, A61P21/04, A61P43/00, C07C335/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/42]
Extension statesBA27.03.2018
ME27.03.2018
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:AMINOAZOLDERIVAT[2018/42]
English:AMINOAZOLE DERIVATIVE[2018/42]
French:DÉRIVÉ D'AMINOAZOLE[2018/42]
Entry into regional phase27.03.2018Translation filed 
27.03.2018National basic fee paid 
27.03.2018Search fee paid 
27.03.2018Designation fee(s) paid 
27.03.2018Examination fee paid 
Examination procedure27.03.2018Examination requested  [2018/42]
27.03.2018Date on which the examining division has become responsible
16.01.2020Amendment by applicant (claims and/or description)
27.02.2020Communication of intention to grant the patent
24.06.2020Fee for grant paid
24.06.2020Fee for publishing/printing paid
24.06.2020Receipt of the translation of the claim(s)
Opposition(s)07.05.2021No opposition filed within time limit [2021/28]
Fees paidRenewal fee
13.12.2018Renewal fee patent year 03
09.12.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.12.2016
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
MT05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
IE09.12.2020
LU09.12.2020
BE31.12.2020
CH31.12.2020
LI31.12.2020
[2022/34]
Former [2022/32]HU09.12.2016
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MK05.08.2020
MT05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
IE09.12.2020
LU09.12.2020
CH31.12.2020
LI31.12.2020
Former [2022/27]HU09.12.2016
AL05.08.2020
AT05.08.2020
CY05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
MT05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
TR05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
IE09.12.2020
LU09.12.2020
CH31.12.2020
LI31.12.2020
Former [2021/52]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
IE09.12.2020
LU09.12.2020
CH31.12.2020
LI31.12.2020
Former [2021/47]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
IE09.12.2020
LU09.12.2020
Former [2021/46]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
IE09.12.2020
Former [2021/40]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
MC05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/36]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SI05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/34]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
IT05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/28]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SK05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/25]AL05.08.2020
AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/22]AT05.08.2020
CZ05.08.2020
DK05.08.2020
EE05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RO05.08.2020
RS05.08.2020
SE05.08.2020
SM05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/21]AT05.08.2020
DK05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/12]AT05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
NL05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/10]AT05.08.2020
ES05.08.2020
FI05.08.2020
HR05.08.2020
LT05.08.2020
LV05.08.2020
PL05.08.2020
RS05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
IS05.12.2020
PT07.12.2020
Former [2021/09]AT05.08.2020
ES05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
GR06.11.2020
PT07.12.2020
Former [2021/08]ES05.08.2020
FI05.08.2020
LT05.08.2020
SE05.08.2020
BG05.11.2020
NO05.11.2020
PT07.12.2020
Former [2021/07]FI05.08.2020
LT05.08.2020
NO05.11.2020
Documents cited:Search[IA]WO2004041277  (MERCK & CO INC [US], et al) [I] 1-10,12-14 * claims 1, 4, 18 * [A] 11;
 [A]US2009036419  (CHEN WEIRONG [US], et al) [A] 1-14* scheme V; page 95 *
International search[A]JPH0680653  (BAYER AG) [A] 1-15 * , entire text & US 5256632 A & EP 0569810 A1 & DE 4215878 A *;
 [A]JPH0940607  (ZENECA LTD) [A] 1-15 * , entire text & US 5834468 A & US 6057345 A & US 2003/0139418 A1 & EP 0752421 A1 *;
 [A]WO9815530  (FUJISAWA PHARMACEUTICAL CO [JP], et al) [A] 1-15 * , entire text & JP 2000-159749 A & US 6166219 A & US 6352985 B1 & WO 1997/024334 A1 & EP 0882718 A1 *;
 [A]WO9900359  (FUJISAWA PHARMACEUTICAL CO [JP], et al) [A] 1-15 * , entire text & US 6242474 B1 & EP 1000932 A1 *;
 [A]WO9900373  (FUJISAWA PHARMACEUTICAL CO [JP], et al) [A] 1-15 * , entire text & US 6420409 B1 & EP 1020452 A1 & AU 7934698 A & CN 1268123 A & KR 10-2001-0014166 A *;
 [A]JP2005537333  (Novo Nordisk A/S) [A] 1-15 * , entire text & US 2003/0138416 A1 & US 2004/0122235 A1 & US 2008/0119454 A1 & US 2008/0119455 A1 & US 2006/0183783 A1 & US 2011/0301158 A1 & WO 2004/002481 A1 & WO 2003/047626 A1 & EP 1453541 A1 & EP 1531815 A1 & EP 2471533 A1 & CN 1678311 A *;
 [A]WO2006114274  (GLAXO GROUP LTD [GB], et al) [A] 1-15 * , entire text & JP 2008-539183 A & US 2008/0207708 A1 & EP 1874776 A1 *;
 [A]JP2007302617  (MITSUI CHEMICALS INC) [A] 1-15 * , entire text (Family: none) *;
 [A]JP2009513563  (Xenon Pharmaceuticals Inc.) [A] 1-15 * , entire text & US 2010/0152187 A1 & US 2013/0096056 A1 & WO 2007/130075 A1 & EP 2029138 A1 & EP 2540296 A1 & CA 2618646 A & CN 101208089 A *;
 [A]WO2010012793  (BAYER CROPSCIENCE SA [FR], et al) [A] 1-15 * , entire text (Family: none) *;
 [A]WO2010018714  (MITSUI CHEMICALS AGRO INC [JP], et al) [A] 1-15 * , entire text & JP 2013-256522 A & US 2011/0201687 A1 & US 2013/0231392 A1 & US 2013/0310459 A1 & US 2011/0137068 A1 & US 2014/0296560 A1 & US 2016/0297750 A1 & WO 2010/018857 A1 & EP 2319830 A1 & EP 2322502 A1 & KR 10-2011-0039370 A & CN 102119143 A *;
 [A]WO2014017093  (KYORIN SEIYAKU KK [JP], et al) [A] 1-15 * , entire text & JP 2015-178458 A *;
 [A]JP2015516437  (Abbvie Inc.) [A] 1-15 * , entire text & US 2014/0336167 A1 & US 2016/0193209 A1 & WO 2013/170118 A1 & EP 2850081 A1 & CA 2870566 A & CN 104271572 A *;
 [A]  - MARUGAN JUAN J. et al., "Evaluation of 2- thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d] pyrimidin-4(1H)-one analogues as GAA activators", European Journal of Medicinal Chemistry, (20100000), vol. 45, no. 5, pages 1880 - 1897, XP026976508 [A] 1-15
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.